CY1114045T1 - Φαρμακευτικη συνθεση με παρατεταμενη απελευθερωση οξικης οκτρεοτιδης - Google Patents
Φαρμακευτικη συνθεση με παρατεταμενη απελευθερωση οξικης οκτρεοτιδηςInfo
- Publication number
- CY1114045T1 CY1114045T1 CY20131100458T CY131100458T CY1114045T1 CY 1114045 T1 CY1114045 T1 CY 1114045T1 CY 20131100458 T CY20131100458 T CY 20131100458T CY 131100458 T CY131100458 T CY 131100458T CY 1114045 T1 CY1114045 T1 CY 1114045T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pharmaceutical composition
- acetective
- liberation
- term
- long
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Η εφεύρεση αυτή αναφέρεται σε φαρμακευτική σύνθεση παρατεταμένης απελευθέρωσης η οποία περιέχει σωματοστατίνη ή ανάλογο σωματοστατίνης, η οποία προορίζεται για χρήση στη θεραπεία και/ή την πρόληψη της διάρροιας και για χρήση στην παρασκευή φαρμάκου θεραπείας και/ή πρόληψης της διάρροιας.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200703103A ES2324009B1 (es) | 2007-11-23 | 2007-11-23 | Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo. |
EP08855638A EP2223684B1 (en) | 2007-11-23 | 2008-11-21 | Pharmaceutical composition with prolonged release of octreotide acetate |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1114045T1 true CY1114045T1 (el) | 2016-07-27 |
Family
ID=40589822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131100458T CY1114045T1 (el) | 2007-11-23 | 2013-06-11 | Φαρμακευτικη συνθεση με παρατεταμενη απελευθερωση οξικης οκτρεοτιδης |
Country Status (13)
Country | Link |
---|---|
US (1) | US20110124563A1 (el) |
EP (1) | EP2223684B1 (el) |
AR (1) | AR069420A1 (el) |
CL (1) | CL2008003489A1 (el) |
CY (1) | CY1114045T1 (el) |
DK (1) | DK2223684T3 (el) |
ES (2) | ES2324009B1 (el) |
HR (1) | HRP20130447T1 (el) |
PL (1) | PL2223684T3 (el) |
PT (1) | PT2223684E (el) |
SI (1) | SI2223684T1 (el) |
TW (1) | TWI463991B (el) |
WO (1) | WO2009068708A2 (el) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017053346A1 (en) | 2015-09-21 | 2017-03-30 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulations |
US11266608B2 (en) | 2015-09-25 | 2022-03-08 | Jennifer J. Kang-Mteler | Biodegradable extended release microsphere-hydrogel ocular drug delivery system and method |
US10980882B2 (en) * | 2015-09-25 | 2021-04-20 | Jennifer J. KANG-MIELER | Biodegradable microsphere-hydrogel ocular drug delivery system |
CA3057438A1 (en) | 2017-03-20 | 2018-09-27 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulaitons |
JP7187738B2 (ja) | 2017-07-17 | 2022-12-13 | メディンセル | 医薬組成物 |
FR3079421A1 (fr) * | 2018-03-28 | 2019-10-04 | Edix Sa | Presentations injectables, seringues et compositions a liberation prolongee et/ou controlee de lanreotide |
US20240100012A1 (en) | 2021-01-18 | 2024-03-28 | Mark Hasleton | Pharmaceutical dosage form |
WO2023281406A1 (en) | 2021-07-06 | 2023-01-12 | Mark Hasleton | Treatment of serotonin reuptake inhibitor withdrawal syndrome |
WO2023092148A1 (en) * | 2021-11-22 | 2023-05-25 | SpecGx LLC | Injectable sustained release pharmaceutical composition |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3678308D1 (de) * | 1985-02-07 | 1991-05-02 | Takeda Chemical Industries Ltd | Verfahren zur herstellung von mikrokapseln. |
US5538739A (en) * | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
SE9100610D0 (sv) * | 1991-03-04 | 1991-03-04 | Procordia Ortech Ab | Bioresorbable material for medical use |
US5980945A (en) * | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
US6214792B1 (en) * | 1996-04-12 | 2001-04-10 | David Lew Simon | Method for treating acute and severe diarrhea |
DE19621533A1 (de) * | 1996-05-29 | 1997-12-04 | Bosch Gmbh Robert | Elektromotorische Bremsvorrichtung |
US6150333A (en) * | 1998-07-30 | 2000-11-21 | Biomeasure, Inc. | Methods of using a somatostatin analogue |
ES2169980B1 (es) * | 1999-12-17 | 2003-11-01 | Lipotec Sa | Microcapsulas para la liberacion prolongada de farmacos. |
KR100466637B1 (ko) * | 2003-06-26 | 2005-01-13 | 주식회사 펩트론 | 서방성 미립구의 혼합 제형을 연속한 단일 공정으로제조하는 방법 |
CN102935069A (zh) * | 2003-07-15 | 2013-02-20 | Pr药品有限公司 | 控释组合物的制备方法 |
AU2006328950B2 (en) * | 2005-12-22 | 2010-07-29 | Novartis Ag | Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers |
-
2007
- 2007-11-23 ES ES200703103A patent/ES2324009B1/es active Active
-
2008
- 2008-11-21 TW TW097145180A patent/TWI463991B/zh not_active IP Right Cessation
- 2008-11-21 SI SI200830961T patent/SI2223684T1/sl unknown
- 2008-11-21 US US12/744,106 patent/US20110124563A1/en not_active Abandoned
- 2008-11-21 WO PCT/ES2008/000731 patent/WO2009068708A2/es active Application Filing
- 2008-11-21 EP EP08855638A patent/EP2223684B1/en not_active Not-in-force
- 2008-11-21 DK DK08855638.6T patent/DK2223684T3/da active
- 2008-11-21 ES ES08855638T patent/ES2414472T3/es active Active
- 2008-11-21 PT PT88556386T patent/PT2223684E/pt unknown
- 2008-11-21 PL PL08855638T patent/PL2223684T3/pl unknown
- 2008-11-24 AR ARP080105093A patent/AR069420A1/es unknown
- 2008-11-24 CL CL2008003489A patent/CL2008003489A1/es unknown
-
2013
- 2013-05-22 HR HRP20130447AT patent/HRP20130447T1/hr unknown
- 2013-06-11 CY CY20131100458T patent/CY1114045T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
WO2009068708A3 (es) | 2009-07-16 |
WO2009068708A2 (es) | 2009-06-04 |
EP2223684A2 (en) | 2010-09-01 |
TWI463991B (zh) | 2014-12-11 |
ES2324009B1 (es) | 2010-05-21 |
WO2009068708A8 (es) | 2010-10-21 |
ES2324009A1 (es) | 2009-07-28 |
CL2008003489A1 (es) | 2009-05-29 |
ES2414472T3 (es) | 2013-07-19 |
US20110124563A1 (en) | 2011-05-26 |
DK2223684T3 (da) | 2013-06-17 |
EP2223684B1 (en) | 2013-03-27 |
TW200936157A (en) | 2009-09-01 |
PL2223684T3 (pl) | 2013-08-30 |
HRP20130447T1 (en) | 2013-06-30 |
SI2223684T1 (sl) | 2013-07-31 |
AR069420A1 (es) | 2010-01-20 |
PT2223684E (pt) | 2013-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1114045T1 (el) | Φαρμακευτικη συνθεση με παρατεταμενη απελευθερωση οξικης οκτρεοτιδης | |
CY1124103T1 (el) | Δοσολογικο σχημα που σχετιζεται με ενεσιμους εστερες παλιπεριδονης μακρας δρασης | |
CY1120389T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει εναν glp-1-αγωνιστη, μια ινσουλινη και μεθειονινη | |
CY1123549T1 (el) | Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης | |
CY1118452T1 (el) | Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης | |
CY1119952T1 (el) | Συνδυασμος μιας ινσουλινης και ενος glp-1-αγωνιστη | |
CY1117869T1 (el) | Φαρμακοτεχνικες μορφες για απο του στοματος απελευθερωση προσροφητικων στο εντερο | |
CY1117143T1 (el) | Νεα καρβονυλιωμενα (αζα)κυκλοεξανια ως προσδετες του d3 υποδοχεα ντοπαμινης | |
ECSP11010760A (es) | Derivados de quinoxalindiona | |
CY1116264T1 (el) | Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2 | |
CY1113315T1 (el) | Ιμιδαζολοκαρβοξαμιδια | |
CL2012003026A1 (es) | Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad. | |
ECSP088763A (es) | Nuevas combinaciones terapéuticas para el tratamiento de la depresión | |
CY1111354T1 (el) | Συστασεις αναστολεα ddp iv | |
CY1117582T1 (el) | Χρηση μιμοτοπων των α-συνουκλεϊνης επιτοπων για θεραπεια ασθενειων σωματος lewy | |
CL2008001855A1 (es) | Compuestos ciclicos condensados derivados del boro; composicion farmaceutica; y uso en el tratamiento y/o prevencion de una enfermedad infecciosa. | |
UY31145A1 (es) | Derivado de 17b+ciano-18a-homo-19-nor-androst-4-eno, su uso y medicamento que lo contiene | |
CY1121465T1 (el) | Μεθοδοι και συνθεσεις για τη θεραπεια της φλεγμονωδους νοσου του εντερου | |
CY1114960T1 (el) | Συνθεσεις που περιλαμβανουν τραμαδολη και σελεκοξιμπη στην θεραπεια πονου | |
GT200800187A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
CY1113435T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει παραγωγο πυραζινης, και μεθοδος χρησης παραγωγου πυραζινης σε συνδυασμο | |
CL2009000309A1 (es) | Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2. | |
CY1114735T1 (el) | Θεραπευτικες συνθεσεις οι οποιες περιεχουν εναν ειδικο ανταγωνιστη του υποδοχεα της ενδοθηλινης και εναν αναστολεα της pde5 | |
CL2008002049A1 (es) | Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
CL2009000119A1 (es) | Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer. |